Abstract
The motivation for this study was the prevalence of A1-AT deficiency among patients with chronic non-specific lung diseases (from 15-26.9% in heterozygous to 5.6% in homozygous deficiency [3, 4]), as well as the low level of study of this inhibitor in patients with chronic bronchitis, in particular when the disease is complicated by respiratory failure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
